https://www.live-feeds.com/feed/sanofi-pays-dupixent-partner-regeneron-1b-upfront-for-4-early-stage-assets-to-ignite-r-dContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/sanofi-pays-dupixent-partner-regeneron-1b-upfront-for-4-early-stage-assets-to-ignite-r-dhttps://www.live-feeds.com/feed/sanofi-pays-dupixent-partner-regeneron-1b-upfront-for-4-early-stage-assets-to-ignite-r-d#u98905Sun, 04 Oct 2026 13:32:12 +0000Sanofi is expanding its alliance with Regeneron through an upfront payment of $1 billion for four early-stage assets. The agreement aims to ignite research and development while funding the continued search for a successor to Dupixent. Along with the asset acquisition, the partnership involves a total financial commitment of up to $8 billion for drug development. The arrangement also resolves an existing legal dispute between the two pharmaceutical companies, building upon their established immunology collaboration.Why it mattersSanofi and Regeneron maintain a long-standing partnership centere